|

Axitinib (VEGF-TKI) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University First Hospital1

Indications

  • Renal Cancer Metastatic1
  • Targeted Therapy1
  • Radiation Therapy1
  • Immunotherapy1
  • Cancer1

Other1 trial

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.